Results 171 to 180 of about 5,348,587 (297)

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields-treated glioblastoma, IDH wildtype patients. [PDF]

Brain Pathol
Nückles J, Jelgersma C, Siewert C, Osberg B, Schmid S, Koch A, Perez E, Teichmann D, Misch M, Karbe AG, Ukrow S, Harter PN, Stassart RM, Vajkoczy P, Onken J, Capper D.   +15 more
europepmc   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Comment on "Preoperative Hemoglobin Decline Is Not an Independent Prognostic Factor for Mortality in Older Hip Fracture Patients". [PDF]

Geriatr Gerontol Int
Zhang Z, Chen M.
europepmc   +1 more source

Prognostic factors in IUI

JBRA Assisted Reproduction, 2019
Bahadur, Gulam, Homburg, Roy
openaire   +2 more sources

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Extracapsular Nodal Extension as a Key Prognostic Factor in FIGO IIIC Endometrial Carcinoma: A Clinic-Pathologic and Molecular Analysis. [PDF]

Cancers (Basel)
Li L, Geng C, Feng N, Zhang S, Cao L, Cao W, Yang B, Ma Y, Zhang S, Xiao H, Chen Y, Zhang L, Li C, Li X, Li Y, Qi L.   +15 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Low CT-derived vertebral attenuation as a prognostic factor in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. [PDF]

Front Oncol
Jiang S, Ren Y, Wang Y, Li Y, Miao L, Liu W, Zhou G.   +6 more
europepmc   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. [PDF]

Oncogene
Sharbeen G, Gonzales-Aloy E, Youkhana J, Kokkinos J, Ignacio RMC, McCarroll JA, Raina AS, Kopecky C, Liu J, Mawson A, Nunez A, Boyer C, Erkan M, Goldstein D, Haghighi KS, Timpson P, Warren SC, Murphy KJ, Gill AJ, Johns AL, Chou A, Australian Pancreatic Cancer Genome Initiative (APGI), Pandzic E, Fok S, Whan R, Gebski V, Morton JP, Apte M, Phillips PA.   +28 more
europepmc   +1 more source